Core Insights - BillionToOne, a molecular diagnostics company, has filed for an IPO to raise up to $100 million [1][2] - The company focuses on developing prenatal and oncology diagnostic technologies using its single-molecule next-generation sequencing (smNGS) platform [1] Company Overview - Founded in 2016 and headquartered in Menlo Park, California, BillionToOne reported revenue of $209 million for the 12 months ending June 30, 2025 [2] - The company plans to list on the NASDAQ under the ticker symbol "BLLN" [2] Product Development - In 2019, BillionToOne launched its first prenatal testing product, UNITY, which is the world's first non-invasive prenatal testing technology based on cell-free DNA [1] - In 2023, the company introduced two complementary liquid biopsy products: Northstar Select for treatment guidance and Northstar Response, which quantifies cancer burden at the single-molecule level without tissue biopsy [1]
分子诊断公司BillionToOne(BLLN.US)申请美股IPO 拟筹资1亿美元